Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Inventory (2021 - 2025)

InMed Pharmaceuticals has reported Inventory over the past 5 years, most recently at $947898.0 for Q4 2025.

  • For Q4 2025, Inventory fell 14.09% year-over-year to $947898.0; the TTM value through Dec 2025 reached $947898.0, down 14.09%, while the annual FY2025 figure was $961173.0, 22.76% down from the prior year.
  • Inventory for Q4 2025 was $947898.0 at InMed Pharmaceuticals, up from $890807.0 in the prior quarter.
  • Over five years, Inventory peaked at $2.5 million in Q2 2022 and troughed at $744839.0 in Q4 2023.
  • A 5-year average of $1.3 million and a median of $1.2 million in 2024 define the central range for Inventory.
  • Biggest five-year swings in Inventory: soared 63.17% in 2022 and later crashed 53.84% in 2023.
  • Year by year, Inventory stood at $988822.0 in 2021, then soared by 63.17% to $1.6 million in 2022, then crashed by 53.84% to $744839.0 in 2023, then skyrocketed by 48.13% to $1.1 million in 2024, then decreased by 14.09% to $947898.0 in 2025.
  • Business Quant data shows Inventory for INM at $947898.0 in Q4 2025, $890807.0 in Q3 2025, and $961173.0 in Q2 2025.